CARA Cara Therapeutics

$-0.18 (-1.02%)

CARA Stock Analysis Overview

What this means: Cara Therapeutics (CARA) gets an Overall Rank of 57, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. CARA's 57 means that it ranks higher than 57% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full CARA report

Cara Therapeutics (CARA) Analyst Forecast

Next 12 months ➝Current Price$17.5252-week High$27.5552-week Low$8.88MEAN$33.33+90.26%HIGH$40.00+128.31%LOW$19.00+8.45%
  • Last Price$17.52
  • Previous Close$17.70
  • Change $-0.18
  • Open$17.90
  • Volume426,917
  • Avg. Volume (100-day)543,222
  • Market Capitalization$820M
  • Days Range $17.24 - $17.98
  • 52-week Range $8.88 - $27.55
  • Dividend Yield
  • Ex. Dividend Date
  • P-E
  • EPS-2.55
  • Earnings Date08/05/2020
  • SectorHealthcare
  • IndustryBiotechnology
  • Avg. Analyst Rec.
  • Beta1.154
  • PEG Ratio
  • Volatility0.58
  • Average True Range0.06
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.